Back to search results

Kidney Transplant Preemptive Therapy or Prophylaxis for CMV Prevention in D+R Recipients

Abroad (travel likely)RecruitingPHASE3

Conditions

Cytomegalovirus (CMV) · Kidney Transplant; Complications · Kidney Diseases

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

  • University of California, San Francisco School of Medicine, San Francisco, California, United States

    Contact: Study coordinator (Puneet Sood, MD, MPH) · puneet.sood@ucsf.edu · 415-353-1551

  • University of Miami Miller School of Medicine, Miami, Florida, United States

    Contact: Study coordinator (Yoichiro Natori, MD) · yxn138@med.miami.edu · 305-355-5418

  • Emory University School of Medicine, Atlanta, Georgia, United States

    Contact: Study coordinator (Aneesh Mehta, MD) · aneesh.mehta@emory.edu · 404-727-8435

  • Robert Wood Johnson Health Network Barnabas Health, Livingston, New Jersey, United States

    Contact: Study coordinator (Francis Weng, MD) · francis.weng@rwjbh.org · 973-322-5065

  • Medical College of Virginia Commonwealth, Richmond, Virginia, United States

    Contact: Study coordinator (Guarav Gupta, MD) · gaurav.gupta@vcuhealth.org · 804-828-4104
Study leads

  • Abhijit P. Limaye, MD

    Principal Investigator

    University of California, San Francisco

View source on ClinicalTrials.gov(opens in a new tab)